Growth Hormone Therapy Guidelines

Introduction to Growth Hormone Secretagogues

Ipamorelin, a growth hormone secretagogue, should not be used clinically as it lacks FDA approval for human use and has insufficient safety and efficacy data to support its therapeutic application 1

Approved GH therapy should be given at 0.045-0.05 mg/kg body weight per day via subcutaneous injections in the evening, as recommended by established guidelines 1
Both reference and biosimilar GH products are acceptable for use in appropriate clinical scenarios, according to the American Academy of Pediatrics 1
The American College of Endocrinology recommends regular clinic visits every 3-6 months (more frequently for young patients or those with advanced conditions) 1, 2
Monitoring should include height velocity, stature, and pubertal development, skeletal maturation via wrist radiography, thyroid function (TSH and free T3), glucose metabolism parameters, calcium, phosphate, and parathyroid hormone levels, as suggested by the Endocrine Society 1, 2

Growth hormone therapy should be stopped in cases of epiphyseal closure, intracranial hypertension, slipped capital femoral epiphysis, persistent severe hyperparathyroidism, inadequate response despite optimal management, or unexplained decrease in renal function, as recommended by the American College of Endocrinology 1

For patients with legitimate growth disorders or growth hormone deficiency, consultation with a pediatric endocrinologist is recommended for proper diagnosis and treatment planning, according to the American Academy of Pediatrics 3
Use of only FDA-approved growth hormone preparations according to established guidelines is recommended, as suggested by the Endocrine Society 1, 3
Implementation of appropriate monitoring protocols to ensure safety and efficacy is necessary, according to the American College of Endocrinology 1, 3
Consideration of the specific condition being treated (e.g., Prader-Willi syndrome, chronic kidney disease) when determining therapy approach is recommended, as suggested by the National Kidney Foundation 1, 3